stockrowImmunityBio, Inc.
IBRX Healthcare Biotechnology
ImmunityBio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $113.3 million, up 668.3% from fiscal 2024.
- Revenue
- +93.9%
- EPS
- −120.0%
- Free cash flow
- +13.4%
- Total debt
- +57.4%
Quarter to June 2026, against a year earlier
Follow IBRX
Alert me
ImmunityBio, Inc. (IBRX) Revenue growth
ImmunityBio, Inc.'s revenue growth over the twelve months to 30 June 2026 was 192.9%, down 475.4 percentage points from fiscal 2025 (668.3%). Over the past ten years it has ranged from −81.4% (fiscal 2016) to 4,585.1% (fiscal 2019); the current reading is higher than 82% of that period. That is above the Biotechnology industry median of 6.26% and above the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 668.3% | (1,602.27) |
| FY2024 | 2,270.6% | 2,111.41 |
| FY2023 | 159.2% | 233.47 |
| FY2022 | −74.3% | (128.68) |
| FY2021 | 54.4% | 126.90 |
| FY2020 | −72.5% | (4,657.63) |
| FY2019 | 4,585.1% | 4,580.67 |
| FY2018 | 4.44% | 2.17 |
| FY2017 | 2.27% | 83.63 |
| FY2016 | −81.4% | (18.18) |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Jun 2026 | 93.9% | (73.73) |
| Mar 2026 | 167.6% | (239.31) |
| Dec 2025 | 407.0% | (18.12) |
| Sep 2025 | 425.1% | (1,998.81) |
| 42 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| IBRX ImmunityBio, Inc. | 192.9% |
| MDGL Madrigal Pharmaceuticals, Inc. compare | 92.8% |
| TGTX TG Therapeutics, Inc. compare | 76.1% |
| CAI Caris Life Sciences,�Inc. compare | 68.8% |
| PTGX Protagonist Therapeutics, Inc. compare | 34.8% |
| CYTK Cytokinetics, Incorporated compare | 29.9% |
| KRYS Krystal Biotech, Inc. compare | 26.0% |
| TWST Twist Bioscience Corporation compare | 19.2% |
| SYRE Spyre Therapeutics, Inc. compare | −81.8% |
| Biotechnology industry median | 6.26% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on IBRX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement